Company Data

Cadrenal Therapeutics Inc.

Fundamental Analysis:

Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc.
Fundamental Analysis:
Current Price
$0.674 11.96%
Market Cap
Price Target
Refer to Report
52wk Range
$0.395 - $3.14
Advanced Market Data


Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.